Home » Topics » Gastrointestinal, BioWorld Science

Gastrointestinal, BioWorld Science
RSS

Deligoparin does not meet endpoints of pivotal study in ulcerative colitis

Sep. 20, 2002

Nautilus Biotech designs improved interferon alfa

Sep. 20, 2002

Wild-type and lamivudine-resistant hepatitis B virus susceptible to MCC-478

Sep. 19, 2002

Merck and Isis researchers identify new HCV NS5B polymerase inhibitors

Sep. 18, 2002

MLN-02 fails to meet primary endpoint in phase II Crohn's disease trial

Sep. 17, 2002

Phase II Ceplene triple-drug trial cleared to continue

Sep. 17, 2002

Potential for Ono-AE1-329 in the treatment of inflammatory bowel disease

Sep. 17, 2002

Herbal complex safe and effective for the treatment of IBS

Sep. 13, 2002

GenOdyssee's interferon variants show preclinical potential in hepatitis C and cancer

Sep. 13, 2002

Small-molecule HCV NS3 protease inhibitors discovered at Boehringer Ingelheim

Sep. 12, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...